Previous studies have shown that factor IX and its activated form, factor IX., bind to cultured vascular endothelial cells and that cell-bound factor IX. retains its procoagulant activity. The present studies provide evidence that factor IX bound to cultured bovine aortic endothelial cells can be activated. Factor IX activation was assessed by fmnding cleavage of the factor IX molecule on NaDodSO4/polyacrylamide gel electrophoresis and by the generation of procoagulant activity as assessed by thrombin-treated factor VIII-dependent generation of factor X. activity. Cell-bound factor IX (0.8 jig per 4 x 108 cells per ml) could be activated by factor XI. (5 pg/ml) or by factor VII, (0.1 pg/ml) without exogenous tissue factor when endothelial cells were treated with phorbol ester and acquired tissue factor-like procoagulant activity. Regardless of how factor IX was activated, the cell-bound factor IX, required thrombin-treated factor VIII and calcium, but not exogenous phospholipid, to activate factor X. In further experiments, factor X bound to endothelial cells specifically and reversibly with a dependence on calcium and with a lower affinity (half-maximal at 480 nM) than factor IX. At saturation, 9.1 x 106 factor X molecules were bound per cell. After activation offactor X by factor IX., approximately 50% of the factor X,. formed could be eluted from the cells by 10 mM EDTA, suggesting that the factor X,. was cell associated. These observations indicate that endothelial cells can bind and promote the activation of factors IX and X in the absence of platelets or exogenous phospholipid. Human factor XIa was a gift of Paul Bajaj, University of California (San Diego). Factor VII was prepared as described (5) and was activated at 37°C in the presence of 10 mM CaC12 by elution from celite (6, 7) coupled to CNBr-activated Sepharose (Pharmacia). Activation of factor VII was complete by 90 min as monitored by coagulant assay (8) and NaDodSO4/10% PAGE (9). Factor X1 was isolated to homogeneity by the method of Fujikawa et al. (10) and tritiated as described by Silverberg et al. (11). Factor Xa was prepared using the purified factor X activator from Russell viper venom (12) immobilized on CNBr-activated Sepharose. Activation was complete by coagulant assay (13) and NaDodSO4/ PAGE (9) after 45 min. Human a-thrombin (2.5 NIH units/,ug) was a gift from J. W. Fenton (New York State Department of Health) (14). Factor VIII was prepared from bovine plasma by a combination offractional polyethylene glycol 6000 precipitation (15) and gel filtration (Sepharose CL-4B) and was generously provided by M. Chopek (University of Washington). Factor VIII (1.3 units/ml before activation) was activated with thrombin (0.01 NIH unit/ml) for 4 min at 37°C in 50 mM Tris HCI, pH 8.0/175 mM NaCl/0.2% bovine serum albumin and the product was designated factor VIII, (16) . Factor VIIIt coagulant activity (16) was stable for up to 7 min. Protein concentrations were determined colorimetrically (17).
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Cultured bovine aortic endothelial cells (BAEC) have highaffinity binding sites for factors IX/IXa (1) (2) (3) . The functional significance of this binding as a potential mechanism for localizing procoagulant activity depends on the ability of cellbound factor IX to be activated and the activity of cell-bound factor IXa in activation of factor X. This study reports the activation of cell-bound factor IX by the contact and tissue factor pathways. Having previously shown that cell-bound factor IXa retains clotting activity (3), we now report that cell-bound factor 1Xa can activate factor X in the absence of exogenous phospholipid but in the presence of added factor VIII. Interaction of factor X, the substrate for this reaction, with endothelial cells has been investigated in view of the possible importance of vessel wall in factor IX/X activation.
METHODS
Coagulation Factors. Bovine coagulation proteins were used throughout these studies except where otherwise specified. Factor IX was isolated by the method of Fujikawa et al. (4) or was generously provided by Charles Esmon (Oklahoma Medical Research Foundation). The factor IX was tritiated, activated, and characterized as described (3) .
Human factor XIa was a gift of Paul Bajaj, University of California (San Diego). Factor VII was prepared as described (5) and was activated at 37°C in the presence of 10 mM CaC12 by elution from celite (6, 7) coupled to CNBr-activated Sepharose (Pharmacia). Activation of factor VII was complete by 90 min as monitored by coagulant assay (8) and NaDodSO4/10% PAGE (9) . Factor X1 was isolated to homogeneity by the method of Fujikawa et al. (10) and tritiated as described by Silverberg et al. (11) . Factor Xa was prepared using the purified factor X activator from Russell viper venom (12) immobilized on CNBr-activated Sepharose. Activation was complete by coagulant assay (13) and NaDodSO4/ PAGE (9) after 45 min. Human a-thrombin (2.5 NIH units/,ug) was a gift from J. W. Fenton (New York State Department of Health) (14) . Factor VIII was prepared from bovine plasma by a combination offractional polyethylene glycol 6000 precipitation (15) and gel filtration (Sepharose CL-4B) and was generously provided by M. Chopek (University of Washington). Factor VIII (1.3 units/ml before activation) was activated with thrombin (0.01 NIH unit/ml) for 4 min at 37°C in 50 mM Tris HCI, pH 8.0/175 mM NaCl/0.2% bovine serum albumin and the product was designated factor VIII, (16) . Factor VIIIt coagulant activity (16) was stable for up to 7 min. Protein concentrations were determined colorimetrically (17) .
Cell Culture and Suspension of BAEC. BAEC were isolated from calf aortas and cultured as described (3) . Cells in these experiments were from passages 2-13 and were used within 24 hr of achieving confluence. Confluent BAEC in 10 x 35 mm culture dishes were suspended as follows: the monolayer was washed twice with 10 mM Hepes/137 mM NaCl/4 mM KCI/11 mM glucose, pH 7.45 (buffer A) and then incubated with Dulbecco's calcium/magnesium-free phosphate-buffered saline/25 mM NaHCO3/10 mM sucrose/1 mM EDTA (1 ml per dish). After 10 min at 37°C, the cells were removed from the dishes, centrifuged at 135 x g for 5 min and suspended in buffer A/10 mM CaCl2 containing fatty acid-free bovine serum albumin at 2 mg/ml (buffer B) to a final concentration of 4 
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Medical Sciences: Stern et aLP 5 min) between washes. In experiments using [3H]factor IX, the radioactivity in the last wash was at the background level. Studies with [3H]factor IX showed binding of similar affinity to that reported with monolayers (3) with 106 cells specifically binding a maximum of 34 fmol of factor IX (nonspecific binding, 21%) and half-maximal binding occurring at a total factor IX concentration of =2 nM. For activation studies,' factor IX was bound to the cells and unbound ligand was washed away. Cells were then suspended in buffer BD, and activating enzyme, factor XIa, or VIIa was added for 10 min at 230C. After cells were washed again, factors VIII, and X were added and the amount of cell-bound factor IXa formed was assessed by monitoring factor Xa activity. The binding of j3H]factor IX to phorbol 12-myristate 13-acetate (PMA)-treated BAEC and to control BAEC in monolayer was studied as described (3) .
The binding of [3H]factor X1 to confluent BAEC was also studied as described for factor IX (3) except that binding assays were performed in 24-well cluster dishes With 16-mm wells at 230C without agitation except for an initial mixing of components in the incubation mixture. Cells were washed three times with buffer A, and then 0.2 ml of buffer A/S mM CaCl2 containing fatty acid-free bovine serum albumin at 2 mg/ml (buffer C) was added. Monolayers were equilibrated for 10 min at 230C in buffer C, then tracer and other components of the reaction mixture were added. After the incubation period, monolayers were washed four times (0.5 ml per wash) with ice-cold buffer C for' a total of 6 sec then solubilized and radioactivity was determined.
Assessment of Coagulant Activity. Cell-associated factor IXa coagulant activity was assessed in a two-stage assay. In the first stage, factor VIIIt and factor X were added to the cells, and in the second stage, factor Xa was quantified by measuring the hydrolysis of Bz-Ile-Glu-Gly-Arg-p-nitroanilide (S2222). BAEC with bound factor IXa were suspended in 50 /.l of buffer B and 50 ,ud each offactor X and factor VIIIt (16.5 pug/ml or 0.3 AM unless otherwise specified) were added. The mixture was incubated at 370C and at intervals 25-Jl aliquots were removed and diluted in 475 pl of 50 mM Tris HCl, pH 7.9/175 mM NaCl/10 mM EDTA containing ovalbumin at 0.5 mg/ml; (buffer D); 200 ,Al of this sample was mixed with 300 ,u1 of 3 mM S222-2 and hydrolysis was followed at 405 nM (18) . The amount offactor Xa formed was determined by comparison with the linear portio'n of a standard curve in which known amounts of factor Xa were incubated with S2222 under the same conditions.
Characterization of the Procoagulant Activity of PMATreated BAEC. Endothelial cells were incubated with PMA (Consolidated Midland, Brewster, NY) at a final concentration of 100 ng/ml'[0.1% (vol/vol) acetone] in serum-containing culture medium. After 16 hr at 370C, the cells were washed with buffer A and' suspended as described above. PMA-treated endothelial cells were assayed for procoagulant activity after suspension to final concentration of 106 cells per ml in 50 mM Tris HCI, pH 7.5/100 mM NaCl/0.1% bovine serum albumin. Cell suspensions were incubated with factor VIla (2 nM) and factor X1 (1.2 AuM) in the presence of 10 mM CaCl2 and then assayed for clot-promoting activity using factor VII-deficient plasma (19) and for S2222 hydrolytic activity as described above. Progressive factor X activation, dependent on the presence of factor VI1a, occurred with PMA-treated cells as shown by both assays.
RESULTS
Activation of Cell-Bound Factor IX by Factor XI.. Activation of endothelial cell-bound factor IX by factor XIa was assessed first by cleavage of the radiolabeled molecule as judged by NaDodSO4/PAGE. The radioactivity profile of a NaDodSO4 gel of the EDTA eluate offactor Xa-treated cellbound [3H]factor IX is shown in Fig. 1A . Cleavage was limited but definite. The band labeled a at Mr = 38,000 presumably represents the heavy chain of factor IX with the activation peptide still attached (20) . The band labeled 1 at Mr = 32,000 presumably represents the heavy chain alone (20) . The band reflecting the activation peptide was quite small, suggesting that this peptide is not closely associated with cell-bound factor IXa (3). In the control sample (Fig. 1B) Experiments comparing the procoagulant activity offactor IXa on the cells with that in solution (Fig.' 2) showed that cellbound fac'tor IXa activated factor X in the presence of added factor VI1t and calcium ions whereas =20-fold more factor IXa in solution failed to do so. However, when phospholipid was added to factor IXa in solution, factor X was activated (data not shown). Cell-bound factor IXa activation of factor X in the presence of factor VIIIt occurred with BAEC in suspension'(line a) or in monolayer. The factor Xa generation curve shows a 1-min lag followed by linear factor Xa formation. The reason for this lag is unclear though it has been described by others (16) in cell-free systems.
Factor VI1a Dependent Activation of Cell-Bound Factor IX by PMA-Treated Endothelial Cells. Studies were then made with PMA-treated cells. Factor IX was found to bind similarly to both PMA-treated and control cells (Fig. 3) . As shown simultaneously with factors VI1a and X, factor X activation also occurs. Control experiments (Table 2) showed minimal activation of factors IX and X in the absence of factor VIla with either PMA-treated or control cells.
Interaction of Factor X with Endothelial Cells. 3H-labeled bovine factor X1 binds in a time-dependent manner to BAEC (Fig' 4A) . Studies of the calcium dependence of the -binding (Fig. 4B) showed that specific binding increased with increasing amounts of added calcium in the incubation buffer to a maximum at 5 mM. Binding is partially reversible (Fig.   4C ), as shown by the elution of cell-bound [ Hifactor X. This elution does not appear to be a first-order process and is thus similar to, though faster than, the complex dissociation kinetics of factor IX from BAEC (3). Cell-bound [3H]factor X from the cells was virtually instantaneously eluted by EDTA (Fig. 4C) . The To one series of wells, unlabeled factor X (44 MAM) was added at the beginning of the experiment (o). To a second set of wells, the same amount of unlabeled factor X was added at 20 min (). To a third set of wells, EDTA (final concentration, 10 (Fig. 5) is identical to that of the original factor X tracer. Without reduction, both cell-associated and native tracer have a Mr of 56,000 (Fig. SA) and with reduction of 40,000 (Fig. SB) Fig. 1. and X in the presence of calcium, the factor Xa formed was =50o cell associated (Table 3) .
DISCUSSION
Previous studies demonstrated specific, saturable, high-affinity, calcium-dependent binding of factors of IX and IXa to cultured endothelial cells (1) (2) (3) . As an initial step in determining the functional significance of cell-bound factor IX, we determined whether it could be activated by the contact and tissue factor pathways and found activation via both factor XIa from the contact system and tissue factor-factor Vila. We found, as did Lyberg and colleagues (21) Factor IXa bound to BAEC has been shown to retain its specific procoagulant activity as assessed by ability to accelerate the clotting time of factor IX-deficient plasma (3) . In the present study, purified proteins and direct assay offactor Xa formation were used to assess the activity of cell-bound factor IXa. Factor IXa bound to BAEC activates factor X as assessed by factor Xa cleavage of S2222. Factor VIIIt and calcium are required but not exogenous phospholipid, indi- Proc. NatL Acad Sd USA 81 (1984) cating that endothelial cells can provide the needed phospholipid. How much factor X is cell associated under these conditions is not known. Relationships between these endothelial cell localized reactions and those which occur on the platelet surface is an unexplored area.
Activation of factor IX bound to PMA-treated endothelial cells by factor VIIa indicates that the sequence of activation on the cell surface could be factor VIla cleavage of factor IX with subsequent factor VIII-dependent factor X activation. Alternatively, if factor X bound to BAEC, direct factor X activation on the cell surface could also occur. The data presented here show that factor X binds to BAEC and that, after activation, at least part of the factor Xa remains associated with the cells. Heimark and Schwartz (2) have also observed factor X binding to BAEC. Comparison of the binding offactors IX and X shows that both bind specifically, reversibly, and in a calcium-dependent manner. Activation does not occur with binding in either case. However, the cells bind factor IX with a much higher affinity than they bind factor X, though there are a greater number of factor X binding sites (2, 3) . Since the cultured bovine aortic endothelial cell can bind factors IX and X, and under appropriate stimulation can acquire potent tissue factor-like procoagulant activity, further studies in this system are likely to provide information about the comparative efficiency and the interactions between the activation of factors IX and X on the cell surface. However, the significantly lower affinity of factor X binding suggests that on the cell surface factor VIIa activation of factor IX may occur preferentially. Further studies are required to define the association of factor Xa with the cell surface.
The concentrations of factor XIa (37 nM), VIla (4.4 nM), and X (300 nM) used in this study are similar to the concentrations of these proteins in human plasma whereas the concentration of cell bound factor IXa (5.5 nM) is about 10% the concentration of factor IX in normal plasma. Although in vivo binding remains to be demonstrated, the activity of cellbound factor IXa in vitro suggests its potential physiologic importance. To determine the true physiologic significance of this cellular surface, studies with cultured cells are only the first step and must be followed up with experiments using perfused vascular beds in in vitro and finally in vivo studies.
These findings link a major portion of the prothrombin activation mechanism to the endothelial cell, starting with initiation by tissue factor and extending via factor IX to factor X activation. Factor V is an important cofactor for factor Xa activation of prothrombin (24) , and the recent report of factor V synthesis by the endothelial cell (25) provides the basis for prothrombin activation on the cell surface. Perturbation of the cells, leading to synthesis and expression of tissue factor-like activity, which could then function as a cofactor in the activation of cell-bound factors IX and X, generating a potent cell-associated prothrombin activator, is a potential mechanism for initiating and localizing thrombosis on the en-
